Table 1 Patient baseline demographics and clinical characteristics (Phase II)

From: Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

 

Patients, N =54

%

Median age, years (range)

60 (43–80)

 

Gender

Male

32

59.3

Female

22

40.7

WHO performance status a

0

23

46.0

1

26

52.0

2

1

2.0

Site of primary tumour

Colon

28

51.9

Rectum

20

37.0

Rectosigmoid junction

6

11.1

Number of metastatic sites

1

28

51.8

2

19

35.2

⩾ 3

7

13.0

  1. Abbreviation: WHO=World Health Organization.
  2. Data not available for four patients.
Back to article page